Navigation Links
Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company's Phase III FDA Sickle Cell Treatment Trials
Date:11/19/2012

TORRANCE, Calif., Nov. 19, 2012 /PRNewswire/ -- Following a meeting on November 5, 2012 with the U.S. Food & Drug Administration (FDA), Dr. Yutaka Niihara offered the following remarks:

"The FDA's review group unanimously recommended that we proceed to complete our Phase III trial without any modification to the protocol. The trial is directed to study L-glutamine as a treatment for sickle cell disease.

"We currently have 220 patients enrolled at 32 study sites throughout the United States.  We will continue enrollment until the end of 2012, with an objective to complete the trial in 2013.

"The FDA's recommendation on proceeding to complete the trial follows the preliminary review of a subset of data from the Phase III clinical trial that was completed by an independent third party in August of this year.  Emmaus received its initial authorization from the FDA to begin the Phase III trial in August 2009, with the first patient enrolled in mid-2010.

"We continue to believe that Emmaus is the only company with a Phase III trial underway for a new sickle cell treatment.  With research grants and through the support of friends, family and private investors over the past 20 years, we have progressed to the point where we are confident in our treatment and hopeful it will be in the hands of patients worldwide in the not too distant future."

About Emmaus Medical, Inc.

Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase III clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine technology products. For more information, please visit www.emmausmedical.com.

Contacts:

Media:
Lori Teranishi for Emmaus Medical, Inc.
415-981-1964
lteranishi@iqprinc.com

Investors:
Roger Pondel for Emmaus Medical, Inc.
310-279-5965
rpondel@pondel.com


'/>"/>
SOURCE Emmaus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
2. Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical Trial During Sickle Cell Awareness Month
3. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
4. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
5. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
6. NIH Director Francis S. Collins, M.D., Ph.D. Selected as 2012 Pro Bono Humanum Honoree by Prix Galien USA
7. Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
11. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on ... presentation entitled "High doses of biotin in progressive multiple sclerosis: ... by Professor Ayman Tourbah , Principal Investigator of the ... Academy of Neurology (EAN) in Copenhagen, Denmark ... take place on Sunday, 29 May 2016 from 14:45 to ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en marcha una ... compartir sus mejores prácticas por el mundo y tratar ... Europa, África, Asia y Estados ... combina la transmisión en vivo con mensajería instantánea y ... "Imagine un médico de Medicines sans Frontieres ...
(Date:5/24/2016)... -- ARANZ Medical  Ltd a specialist in ... been named the Coretex Hi-Tech Emerging Company of the Year ... Bruce Davey , CEO of ARANZ Medical says, "This ... to be recognised for the work we are doing to ... 35 countries around the world from Sub-Saharan Africa through to ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has awarded ... provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, May ... Hallack, President and CEO of Medisend, parent organization and home of the General Myers ...
(Date:5/25/2016)... ... 25, 2016 , ... CloudLIMS, joins an elite number of companies that have ... list of 2016 by CIOReview. , In a deliberate session with the honorary industrial ... 2016 has been concluded with. The positioning is based on evaluation of CloudLIMS’ specialties ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit ... unique integrative medical wellness offerings of Europe, a continent that pioneered the medical/wellness concept ... hear from numerous pioneers in medical wellness, including Henri Chenot, Founder of the Chenot ...
(Date:5/25/2016)... ... May 25, 2016 , ... The University of San ... Health Professions. She will lead a team of more than 100 full-time faculty and ... her role as dean in late August. , Baker comes to USF from the ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp ... a significant spike in their clients' employee participation for their wellness initiatives. ... by implementing a high-deductible health plan with outcome-based deductible incentives. As a result, ...
Breaking Medicine News(10 mins):